Sorrento Therapeutics Inc

NASDAQ:SRNE   2:41:03 PM EDT
7.92
-0.16 (-1.98%)
Products, Regulatory

Sorrento Releases Positive Results Of Phase 1B Trial Of Resiniferatoxin (Rtx) In Reduction Of Osteoarthritis (Oa) Knee Pain

Published: 09/28/2020 13:26 GMT
Sorrento Therapeutics Inc (SRNE) - Sorrento Releases Positive Results of Phase 1b Trial of Resiniferatoxin (rtx) in Reduction of Osteoarthritis (oa) Knee Pain.
Sorrento Therapeutics Inc - No Dose Limiting Toxicities at Any of Doses Tested (up to 30 Ug) at 6 Months Post-administration.
Sorrento Therapeutics Inc - Study is Scheduled to Complete Last Patient Follow-up (1 Year) in 1q2021.
Sorrento Therapeutics Inc - Dose of 12.5ug Selected As Likely Optimal Intra-articular Therapeutic Dose for Future Clinical Trials.
Sorrento Therapeutics Inc - Pain Control in Patients With Advanced Disease (kellgren-lawrence Grade 3/4) Show Persistence of Relief Beyond 6 Months.
Sorrento Therapeutics Inc - to Rapidly Advance Investigational Drug Product Into a Phase 2 Clinical Trial Expected to Start in 2020.
Sorrento Therapeutics Inc - Phase 3 Clinical Trial Expected to Start in 2021 After Completing Additional Enabling Preclinical Studies.